Editors' Note: In response to "Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease," Dr. Suchowersky comments on the need for caution in prescribing tetrabenazine with other medications metabolized by cytochrome P450. Authors Armstrong and Miyasaki encourage clinicians to consult prescribing details before starting any medications. In reference to "Antiplatelets vs anticoagulation for dissection: CADISS nonrandomized arm and meta-analysis," Dr. Caplan points out that most recurrent strokes in patients with cervical dissections occur within 7 days, while the mean time of treatment after symptom onset in this study was 10.8 days. The authors respond that they are looking at the acute phase after cervical dissection in their ongoing randomized arm.

Megan Alcauskas, MD, and Robert C. Griggs, MD

EVIDENCE-BASED GUIDELINE: PHARMACOLOGIC TREATMENT OF CHOREA IN HUNTINGTON DISEASE: REPORT OF THE GUIDELINE DEVELOPMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY

Oksana Suchowersky, Alberta, Canada: I read with interest the recent guideline on the treatment of chorea in Huntington disease¹ and the recommendation of using up to 100 mg of tetrabenazine daily. The authors reviewed side effects of this medication including parkinsonism and depression. However, they did not mention that tetrabenazine is metabolized by cytochrome P450 (CYP2D6). Care needs to be taken when tetrabenazine is used with antidepressants such as paroxetine and fluoxetine and other drugs that are inhibitors of CYP2D6. Because individuals with Huntington disease are often treated with these antidepressants, the dose of tetrabenazine should be decreased by 50%.² Secondly, some individuals metabolize tetrabenazine faster than others. If doses more than 50 mg per day are being considered, it is recommended that patients undergo testing for CYP2D6 metabolizer status to determine whether they are slow metabolizers.³ Dosages above 50 mg per day in both of these circumstances will increase the risk of side effects.

Author Response: Melissa J. Armstrong, Baltimore; Janis Miyasaki, Toronto: We thank Dr. Suchowersky for her comments on the treatment of chorea in

Huntington disease guideline.¹ Although we did not address tetrabenazine (TBZ) metabolism in the evidence section of the guideline text, we did refer to this in the clinical context: "US TBZ prescribing information recommends genotyping for CYP2D6, the enzyme responsible for metabolizing TBZ, prior to TBZ use. Whether this advice is followed clinically is unknown. Possible interactions with other medications metabolized by the CYP2D6 system, such as fluoxetine or paroxetine, should be considered during TBZ dosing." The American Academy of Neurology guideline development process is intended to provide a formal assessment of the strength of the evidence in response to a specific question and cannot serve as the sole reference for clinicians considering prescribing any particular agent. Dosing recommendations are based on the evidence formally reviewed. Thus, some details—such as those mentioned by Dr. Suchowersky—cannot be fully captured in guideline publications. We agree with her points and encourage clinicians to consult prescribing information and other resources before choosing the best approach and dosage for their individual patients.

© 2013 American Academy of Neurology

1. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2012;79:597–603.
2. Guay D. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorder. *Am J Geriatr Pharmacother* 2010;8:331–373.
3. Tetrabenazine (Xenazine tablets) [package insert]. Mississauga, Canada: Biovail Corporation; 2008.

ANTIPLATELETS VS ANTICOAGULATION FOR DISSECTION: CADISS NONRANDOMIZED ARM AND META-ANALYSIS

Louis R. Caplan, Boston: The Cervical Artery Dissection in Stroke Study (CADISS-NR) trial concluded that there was no difference in secondary stroke prevention provided by antiplatelet and anticoagulant agents in patients with carotid or vertebral artery dissections.¹ It is important to note that the mean time of treatment after symptom onset was 10.8 days (SD 7.0, range 1–31 days) in this study.

Extensive published data^{2,3} and my personal experience show that most strokes develop within the first 7 days after brain ischemia and the rate of stroke

Neurology[®]

Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology

Oksana Suchowersky, Melissa J. Armstrong and Janis Miyasaki

Neurology 2013;80:970

DOI 10.1212/WNL.0b013e3182885eb3

This information is current as of March 4, 2013

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/80/10/970.1.full
References	This article cites 2 articles, 1 of which you can access for free at: http://n.neurology.org/content/80/10/970.1.full#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://n.neurology.org/content/80/10/970.1.full##otherarticles
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2013 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.